• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 14, 2011

View Archived Issues

Reg-A, Crowd-Funding Bills Expand Options for Biotechs

Attention cash-strapped private biotechs: Whether you're struggling to find a bridge across the valley of death or trapped in a windowless venture portfolio, don't give up hope just yet, because four bills making their way through Congress could revolutionize your options for fundraising. Read More

Alimera and Psivida Sink As Iluvien Rejected Again

Shares of Alimera Sciences Inc. and partner pSivida Corp. plunged Friday afternoon in the wake of a second complete response letter for diabetic macular edema drug Iluvien (fluocinolone acetonide intravitreal insert). Read More

Separating Good from Bad PPAR Gamma Effects May Be Possible

Results from a study published this week suggest a way to get the benefits of one class of diabetes drugs - thiazolidinediones, or TZDs, such Actos (pioglitazone, Takeda Pharmaceutical Co. Ltd.) and Avandia (rosiglitazone, GlaxoSmithKline plc) - without their side effects. Read More

NewLink Prices IPO to Raise Up to $50M for Cancer Vaccine

After nearly a year of anticipation, NewLink Genetics Corp., of Ames, Iowa, priced its initial public offering of 6.2 million shares at $7 per share, with an underwriters' option of 930,000 additional shares. The offering could raise $49.9 million for the biotech, which specializes in cancer immunotherapeutics. Read More

Clinic Roundup

• KAI Pharmaceuticals Inc., of South San Francisco, reported Phase II results showing that KAI-4169, its long-acting intravenous calcium sensing receptor agonist, was effective in treating secondary hyperparathyroidism in patients with chronic kidney disease, with 33 percent and 49 percent reductions in parathyroid hormone (PTH) from baseline in the 5-mg and 10-mg dose groups, respectively (p < 0.05 vs. placebo for both groups). In the 10-mg group, 76 percent of subjects achieved greater than or equal to 30 percent reduction in PTH, and 67 percent of subjects achieved a PTH level 300 less than or equal to pg/mL at the end of the treatment period. Data were presented at the American Society of Nephrology's Kidney Week meeting in Philadelphia. Read More

Stock Movers

Read More

Current Promotion Rules Not a Good Fit for Social Media

In lieu of a much-promised and oft-delayed guidance on social media, biopharma has been told to apply existing guidance on drug promotion to online communication. But in many instances, that's like trying to fit a square peg into a round hole. Read More

Genable Gets $6.8M for Gene Therapy in Retinitis Pigmentosa

DUBLIN, Ireland - Genable Technologies Ltd. raised €5 million (US$6.8) million in a Series B financing round to take forward a mutation-independent gene therapy approach for treating an autosomal-dominant form of retinitis pigmentosa (RP). Read More

Appointments and Advancements

• EnGene Inc., of Vancouver, British Columbia, appointed Richard M. Glickman to its board. Read More

Other News To Note

• Otsuka Pharmaceutical Co. Ltd., of Tokyo, and H. Lundbeck A/S, of Copenhagen, Denmark, said they entered a long-term agreement to develop and commercialize up to five psychiatric and neuroscience products worldwide. Read More

Bench Press

Researchers from the Korean Ewha Women's University identified a population of dendritic cells - immune system cells that present antigens to other immune system cells - which protect against the development of cardiovascular disease. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 25, 2025.
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Gold dollar sign inside gold cog

    Revmed goes global with $2B in capital for RAS(ON) inhibitors

    BioWorld
    Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe